Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

被引：16
作者：
Wang, Yang [1 ]
Li, Jingxin [2 ]
Wang, Yuxiao [1 ]
Gu, Wei [3 ]
Zhu, Fengcai [1 ,2 ]
机构：
[1] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[2] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
clinical trials; high-risk population; immunization strategy; pneumococcal polysaccharide vaccine; vaccine efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYOCARDIAL-INFARCTION; WORKING-AGE ADULTS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; DISEASE EPIDEMIOLOGY;
D O I：
10.1080/21645515.2017.1409316
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people >= 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.
引用
收藏
页码：1003 / 1012
页数：10
相关论文
共 50 条
  • [41] Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
    Kabir, Alamgir
    Randall, Deborah
    Newall, Anthony T.
    Moore, Hannah C.
    Jayasinghe, Sanjay
    Fathima, Parveen
    Liu, Bette
    Mcintyre, Peter
    Gidding, Heather F.
    [J]. VACCINE, 2023, 41 (37) : 5454 - 5460
  • [42] Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011
    Gutierrez Rodriguez, M. A.
    Ordobas Gavin, M. A.
    Garcia-Comas, L.
    Sanz Moreno, J. C.
    Cordoba Deorador, E.
    Lasheras Carbajo, M. D.
    Taveira Jimenez, J. A.
    Martin Martinez, F.
    Iniesta Fornies, D.
    Arce Arnaez, A.
    [J]. EUROSURVEILLANCE, 2014, 19 (40) : 35 - 43
  • [43] Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults
    Ahn, Jong Gyun
    Kim, Han Wool
    Choi, Hee Jung
    Lee, Jin Hwa
    Kim, Kyung-Hyo
    [J]. VACCINE, 2015, 33 (38) : 4770 - 4775
  • [44] Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects
    Schuetz, Katharina
    Hughes, Richard G.
    Parker, Antony
    Quinti, Isabella
    Thon, Vojtech
    Cavaliere, Monica
    Wuerfel, Martina
    Herzog, Wilhelm
    Gessner, J. Engelbert
    Baumann, Ulrich
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (01) : 288 - 296
  • [45] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study
    Lawrence, Hannah
    Pick, Harry
    Baskaran, Vadsala
    Daniel, Priya
    Rodrigo, Chamira
    Ashton, Deborah
    Edwards-Pritchard, Rochelle C.
    Sheppard, Carmen
    Eletu, Seyi D.
    Litt, David
    Fry, Norman K.
    Rose, Samuel
    Trotter, Caroline
    McKeever, Tricia M.
    Lim, Wei Shen
    [J]. PLOS MEDICINE, 2020, 17 (10)
  • [46] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center
    Toshihiro Masuda
    Eiji Nakatani
    Toshihiro Shirai
    Taisuke Akamatsu
    Kanami Tamura
    Shingo Takahashi
    Yuko Tanaka
    Hirofumi Watanabe
    Yoshinari Endo
    Takahito Suzuki
    Mika Saigusa
    Akito Yamamoto
    Satoru Morita
    Yoko Sato
    Kazuhiro Asada
    [J]. BMC Pulmonary Medicine, 21
  • [47] Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy
    Garrido, Hannah M. Garcia
    Schnyder, Jenny L.
    Haydari, Beheshta
    Vollaard, Albert M.
    Tanck, Michael W. T.
    de Bree, Godelieve J.
    Meek, Bob
    Grobusch, Martin P.
    Goorhuis, Abraham
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (02)
  • [48] A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan
    Jiang, Yiling
    Yang, Xiaoqin
    Taniguchi, Kazuko
    Petigara, Tanaz
    Abe, Machiko
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 687 - 697
  • [49] Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy
    Lu, Ching-Lan
    Chang, Sui-Yuan
    Chuang, Yu-Chung
    Liu, Wen-Chun
    Su, Chin-Ting
    Su, Yi-Ching
    Chang, Shu-Fang
    Hung, Chien-Ching
    [J]. VACCINE, 2014, 32 (09) : 1031 - 1035
  • [50] Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature
    Cripps, Allan W.
    Folaranmi, Temitope
    Johnson, Kelly D.
    Musey, Luwy
    Niederman, Michael S.
    Buchwald, Ulrike K.
    [J]. EXPERT REVIEW OF VACCINES, 2021, 20 (03) : 257 - 267
12345